September 26, 2019
Chugai Pharmaceutical said on September 25 that its comprehensive genomic profiling test FoundationOne CDx Cancer Genomic Profile has obtained expanded approval as a companion diagnostic for the PARP inhibitor Lynparza (olaparib) in patients with BRCA-mutated ovarian cancer. The latest approval...read more